Low‑Dose IL‑2 after Lymphodepletion and TIL Infusion Offers Comparable Immune and Clinical Outcomes to High‑Dose IL‑2 in Metastatic Melanoma
Posted innews Oncology

Low‑Dose IL‑2 after Lymphodepletion and TIL Infusion Offers Comparable Immune and Clinical Outcomes to High‑Dose IL‑2 in Metastatic Melanoma

A phase II study in metastatic melanoma found no major differences in response, circulating T‑cell phenotypes, or proliferative signals between high‑dose and low‑dose IL‑2 after lymphodepletion and tumor‑infiltrating lymphocyte (TIL) infusion followed by pembrolizumab, suggesting low‑dose IL‑2 may be a feasible, lower‑toxicity alternative.
Preoperative Pembrolizumab Plus Chemoradiotherapy (PPCT) for Locally Advanced Resectable ESCC: PALACE‑2 Phase 1/2 Results and Immune‑Microenvironment Insights
Posted innews Oncology

Preoperative Pembrolizumab Plus Chemoradiotherapy (PPCT) for Locally Advanced Resectable ESCC: PALACE‑2 Phase 1/2 Results and Immune‑Microenvironment Insights

PALACE‑2 reports that preoperative pembrolizumab combined with chemoradiotherapy produced a 43.2% pathologic complete response in resectable, locally advanced esophageal squamous cell carcinoma, with acceptable short‑term survival and a high rate of grade ≥3 toxicities; IL‑6 emerged as a potential predictive and targetable mediator of response.
Perioperative Pembrolizumab + Trastuzumab with FLOT Achieves High pCR and Feasible Safety in HER2‑Positive Localized Esophagogastric Adenocarcinoma: Interim PHERFLOT Results
Posted inGeneral Surgery news Oncology

Perioperative Pembrolizumab + Trastuzumab with FLOT Achieves High pCR and Feasible Safety in HER2‑Positive Localized Esophagogastric Adenocarcinoma: Interim PHERFLOT Results

Interim results from the phase 2 PHERFLOT trial show a 48.4% pathological complete response and a 67.7% major pathologic response after four cycles of pembrolizumab, trastuzumab and FLOT in localized HER2‑positive esophagogastric adenocarcinoma; safety was consistent with known profiles.
Impact of Antibiotics, Steroids, and PPIs on Survival in Advanced NSCLC Patients Treated with First-Line Pembrolizumab
Posted inClinical Updates news Oncology Specialties

Impact of Antibiotics, Steroids, and PPIs on Survival in Advanced NSCLC Patients Treated with First-Line Pembrolizumab

This nationwide cohort study reveals that certain antibiotics, higher-dose steroids, and proton pump inhibitors are associated with reduced overall survival in advanced NSCLC patients receiving first-line pembrolizumab, underscoring the importance of careful comedication monitoring during immunotherapy.
Lenvatinib Plus Pembrolizumab Shows Promise for Platinum-Refractory Advanced B3 Thymoma and Thymic Carcinoma: Insights from the PECATI Phase 2 Trial
Posted inClinical Updates news Oncology Specialties

Lenvatinib Plus Pembrolizumab Shows Promise for Platinum-Refractory Advanced B3 Thymoma and Thymic Carcinoma: Insights from the PECATI Phase 2 Trial

The PECATI phase 2 trial demonstrates that lenvatinib combined with pembrolizumab offers encouraging antitumour activity and a manageable safety profile in platinum-refractory metastatic B3 thymoma and thymic carcinoma, a population with limited treatment options.